Comments

In 2016, ASHG responded to the NIH’s proposed policy for the sharing of data obtained from NIH-supported or -conducted genome-wide association studies (GWAS). ASHG supports broad access to phenotypic and genotypic data to advance medical research, and supported the proposed policy with changes. Related: Comments to NIH on Genome-Wide Association Studies (November 2006) Read More

In April 2000, the U.S. Secretary’s Advisory Committee on Genetic Testing issued a set of recommendations for the oversight of genetic testing. ASHG voiced general agreement with the recommendations, and provided comments from the perspective of geneticists to further clarify and refine them. Related: Comments on SACGT Preliminary Recommendations on Oversight of Genetic Testing (May... Read More

In 2000, the U.S. Patent and Trademark Office released revised interim guidelines that raised the bar for patent eligibility of nucleic acid sequences. ASHG supports the PTO’s new standard of “specific, substantial and credible” utility in its revised guidelines, and suggested an extension of this standard to keep pace with current and planned research. Related:... Read More

In 1999, the National Bioethics Advisory Commission requested feedback on current regulations, practices, and ethical issues related to the use of human biological materials in research. ASHG commented on many of the recommendations in the NBAC’s draft document and provided additional expertise. Related: ASHG Response to NBAC on the Ethical Issues and Policy Concerns Surrounding... Read More